Treatment of Painful Diabetic Polyneuropathy with Mixed Gangliosides

Naarden, Allan L.; Davidson, Jaime A.; Harris, Leslie J.; Moore, Jeanne; DeFelice, Stephen L.

doi:10.1007/978-1-4684-1200-0_49

Cited by 24 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another therapy that targets nerve pathology, gangliosides, has shown improvement in nerve conduction [211]. However there are complications related to drug delivery [211,212]. Because of the autoimmune nature of diabetes, IgG has been used to ameliorate the immunerelated pathology, particularly in the proxzimal neuropathies and in certain autonomic neuropathies although there is a small risk of anaphylactic reaction [213].…”

Section: Other Treatment Optionsmentioning

confidence: 98%

Pathophysiology and Treatment of Diabetic Peripheral Neuropathy: The Case for Diabetic Neurovascular Function as an Essential Component

Kles

Vinik²

2006

CDR

View full text Add to dashboard Cite

Worldwide, diabetes and its complications are major causes of morbidity, decreased quality of life, mortality and increasing health care costs. Patients with diabetes attempt to control blood pressure, lipids and blood glucose levels to decrease their risk of macrovascular and microvascular complications, such as diabetic peripheral neuropathy (DPN). Even with control of these risk factors for vascular disease, many patients still develop complications. Targeted therapies to the underlying mechanisms of diabetic neuropathy are essential to slow the progression of the disease. This review describes the signs, symptoms and diagnosis of DPN. Additionally, new therapies and the complex etiology that contributes to the development of diabetic neuropathy are described (oxidative stress, hyperglycemia, advanced glycated end products, autoimmunity, neurotrophic factors and protein kinase C beta).

show abstract

Section: Other Treatment Optionsmentioning

confidence: 98%

Pathophysiology and Treatment of Diabetic Peripheral Neuropathy: The Case for Diabetic Neurovascular Function as an Essential Component

Kles

Vinik²

2006

CDR

View full text Add to dashboard Cite

show abstract

“…These compounds are components of nerve membranes and are required for nerve regeneration[190]. In a few studies a reduction in some painful symptoms has been reported[191–193] whereas in others pain relief has not occurred or been formally assessed[194–197].…”

Section: Other Trialsmentioning

confidence: 99%

Painful diabetic neuropathy

1999

View full text Add to dashboard Cite

Summary Chronic painful diabetic neuropathy causes symptoms that can last for many years and severely impair the quality of life of affected patients. This review describes the epidemiology, pathophysiology and treatment of chronic neuropathic pain. Particular emphasis is placed on a comprehensive review of the management of painful symptoms through a detailed review of the published literature using a variety of databases particularly Medline and EMBASE.

show abstract

“…Hence our primary objective for preparing the antibody was to determine whether the intensive immunization of rabbits with highly purified gangliosides would induce any neurological symptoms since several reports have implicated the development of neurological disorders in animals by direct immunization with GM1 (7,8). These reports raise doubts as to the potential benefits of using gangliosides as a therapeutic agent for the treatment of a variety of neurological disorders (9)(10)(11)(12)(13). Here, we show that despite the high titer anti-gangliside antibodies in immunized rabbits for a period of 6 months, no obvious neurological and neuropathological changes in the experimental animals were observed.…”

Section: Introductionmentioning

confidence: 99%

Lack of Apparent Neurological Abnormalities in Rabbits Sensitized by Gangliosides

Dasgupta

2004

Neurochem Res

View full text Add to dashboard Cite

Two very high titer polyclonal antibodies against two ganglioside antigens, GM1 and GD1a, have been raised in New Zealand white rabbits using a homogeneous suspension of the highly purified antigens in Keyhole Limpet Hemocyanin and Freund's adjuvant. The antisera were prepared over a period of 6 months with repeated injections of the ganglioside suspension, followed by an intravenous injection of the purified ganglioside solution, and collecting the serum (approximately 50 ml) at defined time intervals. The GM1-antibody, thus prepared, showed a cross reactivity toward GDlb and asialo-GM1 (GA1), while the GDla-antibody reacted with GD1a, GM1 and GA1 and GD1b as determined by immuno-overlay and ELISA methods. The titer for GM1 antiserum, determined by'ELISA, was greater than 1/10,000 dilution while the titer for GD1a antibody was greater than 1/5000 dilution. No neurological or behavioral abnormality was observed during the period of antiserum production. To evaluate any likely pathological damage caused by such a high titer ganglioside-antibody, autopsy of CNS as well PNS tissues from the rabbits were carried out after the final bleeding. No obvious pathological changes, including demyelination, were noted in any of the four rabbits. These observations cast doubt as to the direct effect of anti-ganglioside antibody induced neurological and pathological disorders.

show abstract

Treatment of Painful Diabetic Polyneuropathy with Mixed Gangliosides

Cited by 24 publications

References 17 publications

Pathophysiology and Treatment of Diabetic Peripheral Neuropathy: The Case for Diabetic Neurovascular Function as an Essential Component

Pathophysiology and Treatment of Diabetic Peripheral Neuropathy: The Case for Diabetic Neurovascular Function as an Essential Component

Painful diabetic neuropathy

Lack of Apparent Neurological Abnormalities in Rabbits Sensitized by Gangliosides

Contact Info

Product

Resources

About